Developmental expression of drug metabolizing enzymes: Impact on disposition in neonates and young children

International Journal of Pharmaceutics

Volumn 452, Issue 1-2, 2013, Pages 3-7

  Hines, R N ^a  

^a CHILDREN S HOSPITAL OF WISCONSIN   (United States)

Author keywords

Cytochrome P450; Early life stages; Flavin containing monooxygenase; Glutathione S transferase; Human hepatic drug metabolizing enzymes; Ontogeny

Indexed keywords

CHLORPROMAZINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; DEXTROMETHORPHAN; DRUG METABOLIZING ENZYME; FLUOXETINE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 2B7; GLUTATHIONE TRANSFERASE A1; GLUTATHIONE TRANSFERASE A2; GLUTATHIONE TRANSFERASE M1; RISPERIDONE; SULFOTRANSFERASE 1A1;

CHROMATIN STRUCTURE; DNA METHYLATION; DRUG DETERMINATION; DRUG DISPOSITION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; ENZYME ACTIVITY; FETUS DEVELOPMENT; FIRST TRIMESTER PREGNANCY; GENETIC VARIABILITY; GENOTYPE; GESTATIONAL AGE; GLOMERULUS FILTRATION RATE; HEALTH CARE FACILITY; HEART OUTPUT; HISTONE MODIFICATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY BLOOD FLOW; KIDNEY CLEARANCE; KIDNEY STRUCTURE; KIDNEY TUBULE; LIVER DEVELOPMENT; LIVER SIZE; METABOLIC CAPACITY; MICROBIOME; NEWBORN; NEWBORN PERIOD; ONTOGENY; ORGANOGENESIS; PERINATAL PERIOD; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; REGULATORY MECHANISM; SHORT SURVEY; THIRD TRIMESTER PREGNANCY; VASCULAR RESISTANCE;

EID: 84884164144     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.05.079     Document Type: Short Survey

References (47)

1. Alcorn, J., McNamara, P.J., 2002. Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin. Pharmacokinet. 41, 959-998. (Pubitemid 35168438)
2. Alcorn, J., McNamara, P.J., 2003. Pharmacokinetics in the newborn. Adv. Drug Del. Rev. 55, 667-686. (Pubitemid 36428679)
3. Barter, Z.E., Bayliss, M.K., Beaune, P.H., Boobis, A.R., Carlile, D.J., Edwards, R.J., Houston, J.B., Lake, B.G., Lipscomb, J.C., Pelkonen, O.R., Tucker, G.T., Rostami-Hodjegan, A., 2007. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr. Drug Metab. 8, 33-45. (Pubitemid 46043890)
4. Barter, Z.E., Chowdry, J.E., Harlow, J.R., Snawder, J.E., Lipscomb, J.C., Rostami-Hodjegan, A., 2008. Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling. Drug Metab. Dispos. 36, 2405-2409.
5. Blake, M.J., Gaedigk, A., Pearce, R.E., Bomgaars, L.R., Christensen, M.L., Stowe, C., James, L.P., Wilson, J.T., Kearns, G.L., Leeder, J.S., 2007. Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin. Pharmacol. Ther. 81, 510-516. (Pubitemid 46452306)
6. Bork, J.A., Rogers, T., Wedlund, P.J., de Leon, J., 1999. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J. Clin. Psychiatry 60, 469-476. (Pubitemid 29369803)
7. Cappiello, M., Giuliani, L., Rane, A., Pacifici, G.M., 1991. Dopamine sulfotransferase is better developed than p-nitrophenol sulfotransferase in the human fetus. Dev. Pharmacol. Ther. 16, 83-88.
8. Cashman, J.R., Camp, K., Fennessey, P.V., Hines, R.N., Mamer, O.A., Mitchell, S.C., Schlenk, D., Smith, R.A., Tjoa, S.S., Williams, D.E., Yannicelli, S., 2003. Biochemical and clinical aspects of the human flavin-containing monooxygenase form 3 (FMO3) related to trimethylaminuria. Curr. Drug Metab. 4, 151-170. (Pubitemid 36443193)
9. Chen, H., Fantel, A.G., Juchau, M.R., 2000. Catalysis of the 4-hydroxylation of retinoic acids by CYP3A7 in human fetal hepatic tissues. Drug Metab. Dispos. 28, 1051-1057. (Pubitemid 30660359)
10. Clewell, H.J., Gentry, P.R., Covington, T.R., Sarangapani, R., Teeguarden, J.G., 2004. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicol. Sci. 79, 381-393. (Pubitemid 38786895)
11. Croom, E.L., Stevens, J.C., Hines, R.N., Wallace, A.D., Hodgson, E., 2009. Human hepatic CYP2B6 developmental expression: the impact of age and genotype. Biochem. Pharmacol. 78, 184-190.
12. de Wildt, S.N., Kearns, G.L., Leeder, J.S., van den Anker, J.N., 1999. Glucuronidation in humans: Pharmacogenetic and developmental aspects. Clin. Pharmacokinet. 36, 439-452. (Pubitemid 29317491)
13. Duanmu, Z., Weckle, A., Koukouritaki, S.B., Hines, R.N., Falany, J.L., Falany, C.N., Kocarek, T.A., Runge-Morris, M., 2006. Developmental expression of aryl, estrogen, and hydroxysteroid sulfotransferases in pre- and postnatal human liver. J. Pharmacol. Exp. Ther. 316, 1310-1317. (Pubitemid 43345307)
14. Edenberg, H.J., 2000. Regulation of the mammalian alcohol dehydrogenase genes. Prog. Nucleic Acid Res. 64, 295-341.
15. Gershanik, J., Boecler, B., Ensley, H., McCloskey, S., George, W., 1982. The gasping syndrome and benzyl alcohol poisoning. N. Engl. J. Med. 307, 1384-1388. (Pubitemid 13244609)
16. Halpern, S.A., 1988. American Pediatrics: The Social Dynamics of Professionalism, 1880-1980. University of California Press, Berkeley.
17. Hamelin, B.A., Turgeon, J., Vallee, F., Belanger, P.M., Paquet, F., LeBel, M., 1996. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin. Pharmacol. Ther. 60, 512-521. (Pubitemid 26414087)
18. Hines, R.N., 2008. Ontogeny of drug metabolism enzymes and implications for adverse drug reactions. Pharmacol. Therapeut. 118, 250-267.
19. Johnson, T.N., Rostami-Hodjegan, A., Tucker, G.T., 2006. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin. Pharmacokinet. 45, 931-956. (Pubitemid 44299829)
20. Johnsrud, E.K., Koukouritaki, S.B., Divakaran, K., Brunengraber, L., Hines, R.N., McCarver, D.G., 2003. Human hepatic CYP2E1 expression during development. J. Pharmacol. Exp. Ther. 307, 402-407. (Pubitemid 37151933)
21. Kearns, G.L., Abdel-Rahman, S.M., Alander, S.W., Blowey, D.L., Leeder, J.S., Kauffman, R.E., 2003. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349, 1157-1167. (Pubitemid 37122329)
22. Kiefer, J.C., 2007. Epigenetics in development. Dev. Dyn. 236, 1144-1156. (Pubitemid 46641355)
23. Klick, D.E., Shadley, J.D., Hines, R.N., 2008. Differential regulation of human hepatic flavin containing monooxygenase 3 (FMO3) by CCAAT/enhancer- binding protein beta (C/EBPβ) liver inhibitory and liver activating proteins. Biochem. Pharmacol. 76, 268-278.
24. Koukouritaki, S.B., Manro, J.R., Marsh, S.A., Stevens, J.C., Rettie, A.E., McCarver, D.G., Hines, R.N., 2004. Developmental expression of human hepatic CYP2C9 and CYP2C19. J. Pharmacol. Exp. Ther. 308, 965-974. (Pubitemid 38263972)
25. Koukouritaki, S.B., Simpson, P., Yeung, C.K., Rettie, A.E., Hines, R.N., 2002. Human hepatic flavin-containing monooxygenase 1 (FMO1) and 3 (FMO3) developmental expression. Pediatr. Res. 51, 236-243. (Pubitemid 34101340)
26. Kubota, T., Yamaura, Y., Ohkawa, N., Hara, H., Chiba, K., 2000. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextramethorphan O-demethylation in different CYP2D6 genotypes. Br. J. Clin. Pharmacol. 50, 31-34. (Pubitemid 30416968)
27. Lacroix, D., Sonnier, M., Moncion, A., Cheron, G., Cresteil, T., 1997. Expression of CYP3A in the human liver. Evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur. J. Biochem. 247, 625-634. (Pubitemid 27308642)
28. Li, W., Gu, Y., James, M.O., Hines, R.N., Simpson, P., Langaee, T.Y., Stacpoole, P.W., 2011. Prenatal and postnatal expression of glutathione transferase zeta 1 in human liver and the roles of haplotype and subject age in determining activity with dichloroacetate. Drug Metab Dispos 40, 232-239.
29. Marill, J., Cresteil, T., Lanotte, M., Chabot, G.G., 2000. Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol. Pharmacol. 58, 1341-1348.
30. Martinez-Jimenez, C.P., Gomez-Lechon, M.J., Castell, J.V., Jover, R., 2005. Transcriptional regulation of the human hepatic CYP3A4: identification of a new distal enhancer region responsive to CCAAT/enhancer-binding protein beta isoforms (liver activating protein and liver inhibitory protein). Mol. Pharmacol. 67, 2088-2101. (Pubitemid 41007791)
31. Mayatepek, E., Kohlmüeller, D., 1998. Transient trimethylaminuria in childhood. Acta Paediatr. 87, 1205-1207. (Pubitemid 28538436)
32. Mitchell, S.C., Smith, R.L., 2001. Trimethylaminuria: the fish malodor syndrome. Drug Metab. Dispos. 29, 517-521. (Pubitemid 32275527)
33. Murry, D.J., Crom, W.R., Reddick, W.E., Bhargava, R., Evans, W.E., 1995. Liver volume as a determinant of drug clearance in children and adolescents. Drug Metab. Dispos. 23, 1110-1116.
34. Noda, T., Todani, T., Watanabe, Y., Yamamoto, S., 1997. Liver volume in children measured by computed tomography. Pediatr. Radiol. 27, 250-252. (Pubitemid 27135415)
35. Ourlin, J.C., Jounaïdi, Y., Maurel, P., Vilarem, M.J., 1997. Role of the liver-enriched transcription factors C/EBPα and DBP in the expression of human CYP3A4 and CYP3A7. J. Hepatol. 26, 54-62.
36. Pearce, R.E., Gotschall, R.R., Kearns, G.L., Leeder, J.S., 2001. Cytochrome P450 involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual CYP3A isoforms. Drug Metab. Dispos. 29, 1548-1554. (Pubitemid 33111587)
37. Ring, J.A., Ghabrial, H., Ching, M.S., Smallwood, R.A., Morgan, D.J., 1999. Fetal hepatic drug elimination. Pharmacol. Therapeut. 84, 429-445.
38. Sonnier, M., Cresteil, T., 1998. Delayed ontogenesis of CYP1A2 in the human liver. Eur. J. Biochem. 251, 893-898. (Pubitemid 28108986)
39. Stefani, G., Slack, F.J., 2008. Small non-coding RNAs in animal development. Nat. Rev. Mol. Cell Biol. 9, 219-230. (Pubitemid 351301826)
40. Stevens, J.C., Hines, R.N., Gu, C., Koukouritaki, S.B., Manro, J.R., Tandler, P.J., Zaya, M.J., 2003. Developmental expression of the major human hepatic CYP3A enzymes. J. Pharmacol. Exp. Ther. 307, 573-582. (Pubitemid 37310671)
41. Stevens, J.C., Marsh, S.A., Zaya, M.J., Regina, K.J., Le, M., Hines, R.N., 2008. Developmental changes in human liver CYP2D6 expression. Drug Metab. Dispos. 36, 1587-1593.
42. Vieira, I., Sonnier, M., Cresteil, T., 1996. Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period. Eur. J. Biochem. 238, 476-483.
43. Weiss, C.F., Glazko, A.J., Weston, J.K., 1960. Chloramphenicol in the newborn infant: a physiological explanation of its toxicity when given in excessive doses. N. Engl. J. Med. 262, 787-794.
44. Yang, D., Pearce, R.E., Wang, X., Gaedigk, R., Wan, Y.J., Yan, B., 2009. Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. Biochem. Pharmacol. 77, 238-247.
45. Zhou, S.F., 2009a. Polymorphism of human cytochrome P450 2D6 and its clinical significance, Part I. Clin. Pharmacokinet. 48, 689-723.
46. Zhou, S.F., 2009b. Polymorphism of human cytochrome P450 2D6 and its clinical significance, Part II. Clin. Pharmacokinet. 48, 761-804.
47. Zhu, H.J., Appel, D.I., Jiang, Y., Markowitz, J.S., 2009. Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver. Drug Metab. Dispos. 37, 1819-1825.